P3 Health Partners Inc. 8-K

What Happened
P3 Health Partners Inc. announced in a Form 8-K filed May 26, 2026 that on May 20, 2026 the Listing Qualifications Staff of The Nasdaq Stock Market notified the company it now complies with Nasdaq Listing Rule 5550(b)(2). This follows a prior notice from Nasdaq on November 28, 2025 that the company had failed to meet at least one of the standards under Rule 5550(b), and the company’s Form 8-K filed May 15, 2026 which the Staff reviewed before reaching its determination.

Key Details

• Nasdaq notified P3 of non-compliance on November 28, 2025 under Nasdaq Listing Rule 5550(b) (standards include $2.5M stockholders’ equity, $35M market value of listed securities, or $500,000 net income from continuing operations).
• On May 20, 2026 the Nasdaq Staff determined the company complies with Rule 5550(b)(2) and has returned to compliance with Nasdaq continued listing requirements.
• The company disclosed the Staff’s determination in a Form 8-K filed with the SEC on May 26, 2026; the company’s May 15, 2026 Form 8-K was the submission the Staff reviewed.
• The May 26, 2026 8-K was signed by CFO Leif Pedersen.

Why It Matters
Restoring compliance with Nasdaq’s continued listing standards removes the immediate risk of delisting tied to the prior notice and keeps the company’s common stock listed on Nasdaq, which preserves liquidity and access to public capital markets for shareholders. Investors should view this as a regulatory relief event grounded in Nasdaq’s determination; the filing does not change the company’s financial results or operational outlook disclosed elsewhere.